SCHEMBL4468631

SCHEMBL4468631

NN1COc2cc(O)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.44
MAOA P21397 1/20 0.36
MAOB P27338 1/20 0.36
ESR2 Q92731 3/20 0.33
ESR1 P03372 2/20 0.33
TTR P02766 1/20 0.33
CA2 P00918 1/20 0.32
CA5A P35218 1/20 0.32
CHRNB4 P30926 4/20 0.31
CHRNA3 P32297 4/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNA4 P43681 1/20 0.31
HTR2B P41595 1/20 0.31
TMEM97 Q5BJF2 1/20 0.31
SIGMAR1 Q99720 1/20 0.31
DRD2 P14416 1/20 0.31
DRD1 P21728 1/20 0.31
DRD4 P21917 1/20 0.31
DRD5 P21918 1/20 0.31
DRD3 P35462 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28136150 0.77 CYP3A4 (0.44) CYP3A4MAOAMAOBESR2ESR1
SCHEMBL2706827 0.73 CYP3A4 (0.40) CYP3A4MAOAMAOBESR2ESR1
SCHEMBL5263086 0.71 ABCG2 (0.44) CA2
Hydrochloric Acid SCHEMBL12469273 0.69 ABCG2 (0.42) CA2
SCHEMBL19270333 0.69 CYP3A4 (0.39) CYP3A4MAOAMAOBESR2CA2
SCHEMBL27992668 0.69 CYP3A4 (0.37) CYP3A4MAOAMAOBESR2ESR1
SCHEMBL22100183 0.67 DRD2 (0.36) CYP3A4ESR2ESR1TTRDRD2
SCHEMBL24524724 0.67 CYP3A4 (0.41) CYP3A4MAOAMAOBCHRNB4CHRNA3
SCHEMBL3330747 0.67 CYP11B1 (0.51) CYP3A4MAOAMAOBCHRNB4CHRNA3
SCHEMBL30967081 0.67 MAPT (0.40) CHRNB4CHRNA3CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1717230-B1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE MSD KK (JP) 2014-08-06 EP disclosed
US-8268842-B2 Fused ring 4-oxopyrimidine derivative MSD K.K. (JP) 2012-09-18 US disclosed
CN-1918128-B fused ring 4-oxo-pyrimidine derivatives BANYU PHARMA CO LTD 2011-01-26 CN disclosed
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2009-08-20 US disclosed
US-7521455-B2 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO. LTD. (JP) 2009-04-21 US disclosed
CN-1918128-A Fused ring 4-oxo-pyrimidine derivatives BANYU PHARMA CO LTD (JP) 2007-02-21 CN disclosed
EP-1717230-A1 FUSED-RING 4-OXOPYRIMIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-02 EP disclosed
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182045-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 CYP3A4 525/4885MAOA 743/4885MAOB 629/4885
US-20090209562-A1 Fused ring 4-oxopyrimidine derivative HRH4, HRH2, HRH3 CYP3A4 525/4885MAOA 743/4885MAOB 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.